
|Videos|November 13, 2020
Imaging and biopsy practices in active surveillance for low-risk prostate cancer
Author(s)Urology Times staff
Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.
Advertisement
In the second installment of J. Brantley Thrasher, MD’s interview with Christopher P. Evans, MD, regarding active surveillance for low-risk prostate cancer, Evans discusses his imaging and biopsy regimens, how he handles PI-RADS 3 lesions, and more. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. Thrasher is executive director of the American Board of Urology, Charlottesville, Virginia.
Advertisement
Related to this article

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.

The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.

In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.

Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.

The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5
